Albireo nets $48.7mm in public stock sale
Executive Summary
Albireo Pharma Inc. (primarily develops liver disease treatments; also has GI projects) netted $48.7mm through a public offering of 2.5mm common shares (including the overallotment) at $20.50. Proceeds are earmarked for Phase III trials of A4250 for progressive familial intrahepatic cholestasis (PFIC); initiation of a trial with A4250 for pediatric cholestatic liver diseases; Phase II study with A3384 for bile acid malabsorption (BAM); and to advance preclinical NASH programs into clinical trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice